SAUNDRA CLARK: Open Payments
NPI 1972839934 · DYER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,285 in 68 payments from 21 companies in 2025. Trend: 2023 $2,048 · 2024 $1,366 · 2025 $1,285
Food & beverage: $1,285
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $169 |
| ABBVIE INC. | 12 | $157 |
| Radius Health, Inc. | 6 | $145 |
| Sumitomo Pharma America, Inc. | 5 | $107 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $102 |
| Novo Nordisk Inc | 4 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $50 |
| Merck Sharp & Dohme LLC | 3 | $49 |
Products named: Tymlos, GEMTESA, XIFAXAN, BREZTRI, AIRSUPRA, GVOKE HYPOPEN, TRELEGY ELLIPTA, VRAYLAR.
Industry payments across IN — which companies pay providers there.
